[Evidence of risedronate for treatment of osteoporosis].
Soen
Satoshi
S
Department of Orthopaedic Surgery and Rheumatology, Nara Hospital, Kinki University School of Medicine.
D015415:Biomarkers / Q000652:urine; D015519:Bone Density; D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D024042:Collagen Type I / Q000652:urine; D012968:Etidronic Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use; D019317:Evidence-Based Medicine; D005260:Female; D005265:Femoral Neck Fractures / Q000517:prevention & control; D006801:Humans; D008297:Male; D015201:Meta-Analysis as Topic; D010024:Osteoporosis / Q000175:diagnosis / Q000188:drug therapy* / Q000378:metabolism; D010455:Peptides / Q000652:urine; D016032:Randomized Controlled Trials as Topic; D000068296:Risedronic Acid; D016103:Spinal Fractures / Q000517:prevention & control
D015415:Biomarkers; D050071:Bone Density Conservation Agents; D024042:Collagen Type I; D010455:Peptides; C052929:collagen type I trimeric cross-linked peptide; D000068296:Risedronic Acid; D012968:Etidronic Acid